Sugi Predict

Sugi Predict / Compounds / SCHEMBL13675649

SCHEMBL13675649

SCHEMBL13675649

CC(C)(C)c1ccc(/C=C/C(=O)Nc2ccccc2CO)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 6/20 0.66
▸ TNIK Q9UKE5 1/20 0.66
▸ NPC1 O15118 4/20 0.57
▸ RAB9A P51151 4/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ LMNA P02545 2/20 0.57
▸ HDAC1 Q13547 1/20 0.54
▸ MAPT P10636 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ MAOB P27338 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ TRPA1 O75762 1/20 0.51
▸ TRPM8 Q7Z2W7 1/20 0.51
▸ MMP1 P03956 2/20 0.50
▸ MMP2 P08253 2/20 0.50
▸ MMP9 P14780 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675865 0.85 TRPV1 (0.61) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675634 0.83 MMP1 (0.72) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675779 0.83 MMP1 (0.74) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675771 0.82 TRPV1 (0.75) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675644 0.82 TRPV1 (0.69) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675867 0.80 TNIK (1.00) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675885 0.80 TRPV1 (1.00) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL13675881 0.79 TRPV1 (0.65) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL4006429 0.78 TRPV1 (1.00) TRPV1TNIKNPC1RAB9ASMN1; SMN2
SCHEMBL4006434 0.78 TRPV1 (1.00) TRPV1TNIKNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 — — US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 — — US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 — — US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 — — US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885TNIK 2410/4885NPC1 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.